HRP20230249T1 - Derivati 4-pirazin-2-ilmetil-morfolina i njihova uporaba kao lijeka - Google Patents
Derivati 4-pirazin-2-ilmetil-morfolina i njihova uporaba kao lijeka Download PDFInfo
- Publication number
- HRP20230249T1 HRP20230249T1 HRP20230249TT HRP20230249T HRP20230249T1 HR P20230249 T1 HRP20230249 T1 HR P20230249T1 HR P20230249T T HRP20230249T T HR P20230249TT HR P20230249 T HRP20230249 T HR P20230249T HR P20230249 T1 HRP20230249 T1 HR P20230249T1
- Authority
- HR
- Croatia
- Prior art keywords
- image
- following structure
- compound
- enantiomer
- treatment
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims 2
- JKLJHSTZIZURSR-UHFFFAOYSA-N 4-(pyrazin-2-ylmethyl)morpholine Chemical class C=1N=CC=NC=1CN1CCOCC1 JKLJHSTZIZURSR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 206010026749 Mania Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- -1 H3CCH2CH2CH2 Chemical group 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- 208000008930 Low Back Pain Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Chemical group 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000009429 distress Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000024335 physical disease Diseases 0.000 claims 1
- 230000035790 physiological processes and functions Effects 0.000 claims 1
- 230000007824 polyneuropathy Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Claims (22)
1. Spoj, naznačen time, da je predstavljen formulom A
[image]
u kojoj
R1 predstavlja metil, etil, propil, izo-propil, ciklopropil, H3CCH2CH2CH2, ciklobutil;
R2 predstavlja fenil koji je opcionalno supstituiran s 1, 2 ili 3 supstitenta odabrana iz skupine koju čine fluor, klor, metil, etil, ciklopropil.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da
R1 predstavlja metil, etil;
R2 predstavlja
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
,
[image]
.
3. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 2, to jest spoj, naznačen time, da se bira iz skupine koju čine:
[image]
[image]
[image]
[image]
4. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 to 3, naznačen time, da ima sljedeću strukturu:
[image]
5. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 to 3, naznačen time, da ima sljedeću strukturu:
[image]
6. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 to 3, naznačen time, da ima sljedeću strukturu:
[image]
7. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 to 3, naznačen time, da ima sljedeću strukturu:
[image]
8. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 to 3, naznačen time, da ima sljedeću strukturu:
[image]
9. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ima sljedeću strukturu:
[image]
10. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ima sljedeću strukturu:
[image]
11. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ima sljedeću strukturu:
[image]
12. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ima sljedeću strukturu:
[image]
13. (S)-enantiomer prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da ima sljedeću strukturu:
[image]
14. Farmaceutski prihvatljiva sol, naznačena time, da je od spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 13.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu kao lijek.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u liječenju i/ili prevenciji bipolarnog poremećaja I u obliku depresije, hipomanije, manije, i u miješanom obliku; bipolarnog poremećaja II; depresivnih poremećaja; velikog depresivnog poremećaja sa ili bez pratećeg anksioznog distresa, miješanih značajki, melankolijskih značajki, netipičnih značajki, psihotičkih značajki koje se podudaraju s raspoloženjem, psihotičkih značajki koja se ne podudaraju s raspoloženjem, katatonije.
17. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u liječenju i/ili prevenciji jednokratne depresivne epizode ili periodičnog velikog depresivnog poremećaja, manjeg depresivnog poremećaja, depresivnog poremećaja s postporođajnim napadom, depresivnih poremećaja s psihotičnim simptomima.
18. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 15 do 17, naznačen time, da se spoj primjenjuje kao dodatak uz liječenje s nekim drugim antidepresivnim lijekom.
19. Spoj za uporabu prema bilo kojem od patentnih zahtjeva 15 do 17, naznačen time, da se spoj primjenjuje kao dodatak u terapiji poremećaja ponašanja.
20. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u liječenju akutne i kronične boli koja se odnosi na neuropatiju, fiziološke procese i fizičke poremećaje, bolest mišićno-koštanog sustava i vezivnog tkiva, poremećaje kod živaca, korjena živaca i pleksusa.
21. Spoj prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da je za uporabu u liječenju dijabetičke neuropatije, polineuropatije, bolova u donjem dijelu leđa, bolova u zglobovima, reumatizma, mijalgije, sindroma fantomskog ekstremiteta s bolovima, sindroma karpalnog kanala.
22. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 14, u mješavini s farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem i/ili nosačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18200943 | 2018-10-17 | ||
| PCT/EP2019/078027 WO2020079039A1 (en) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
| EP19786343.4A EP3867244B1 (en) | 2018-10-17 | 2019-10-16 | 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230249T1 true HRP20230249T1 (hr) | 2023-04-14 |
Family
ID=63878518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230249TT HRP20230249T1 (hr) | 2018-10-17 | 2019-10-16 | Derivati 4-pirazin-2-ilmetil-morfolina i njihova uporaba kao lijeka |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11166958B2 (hr) |
| EP (1) | EP3867244B1 (hr) |
| JP (1) | JP7093468B2 (hr) |
| KR (1) | KR20210079325A (hr) |
| CN (1) | CN112888685B (hr) |
| AR (1) | AR116711A1 (hr) |
| AU (1) | AU2019362330B2 (hr) |
| BR (1) | BR112021004993A2 (hr) |
| CA (1) | CA3113308A1 (hr) |
| CL (1) | CL2021000858A1 (hr) |
| CO (1) | CO2021004612A2 (hr) |
| CR (1) | CR20210184A (hr) |
| DK (1) | DK3867244T3 (hr) |
| DO (1) | DOP2021000069A (hr) |
| EA (1) | EA202191014A1 (hr) |
| EC (1) | ECSP21027009A (hr) |
| ES (1) | ES2940184T3 (hr) |
| FI (1) | FI3867244T3 (hr) |
| HR (1) | HRP20230249T1 (hr) |
| HU (1) | HUE061891T2 (hr) |
| IL (1) | IL282142B2 (hr) |
| JO (1) | JOP20210075A1 (hr) |
| LT (1) | LT3867244T (hr) |
| MA (1) | MA53898B1 (hr) |
| MX (1) | MX2021004418A (hr) |
| PE (1) | PE20211278A1 (hr) |
| PH (1) | PH12021550834A1 (hr) |
| PL (1) | PL3867244T3 (hr) |
| PT (1) | PT3867244T (hr) |
| RS (1) | RS63988B1 (hr) |
| SA (1) | SA521421756B1 (hr) |
| SG (1) | SG11202103806VA (hr) |
| SI (1) | SI3867244T1 (hr) |
| TW (1) | TWI828779B (hr) |
| WO (1) | WO2020079039A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3980401A1 (en) * | 2019-06-04 | 2022-04-13 | Boehringer Ingelheim International GmbH | Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495561B2 (en) | 1999-10-29 | 2002-12-17 | Merck & Co., Inc. | 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
| AU2002338334B8 (en) | 2001-04-03 | 2008-09-18 | Merck & Co., Inc. | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists |
| MXPA04000737A (es) * | 2001-07-24 | 2004-07-08 | Richter Gedeon Vegyeszet | Derivados de piperidina como antagonistas receptores de nmda. |
| US7855201B2 (en) * | 2005-12-06 | 2010-12-21 | Merck Sharp & Dohme. Corp. | Morpholine carboxamide prokineticin receptor antagonists |
| US20110319416A1 (en) * | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| WO2012128582A2 (en) | 2011-03-23 | 2012-09-27 | Hyundai Pharm Co., Ltd. | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME |
| KR101684816B1 (ko) | 2012-10-18 | 2016-12-20 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 활성의 조절제로서 에틴일 유도체 |
| US9676757B2 (en) | 2014-02-27 | 2017-06-13 | Merck Patent Gmbh | Heterocyclic compounds as NaV channel inhibitors and uses thereof |
| WO2016029146A1 (en) | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
| WO2017066368A1 (en) * | 2015-10-14 | 2017-04-20 | Bristol-Myers Squibb Company | Selective nr2b antagonists |
-
2019
- 2019-10-16 TW TW108137247A patent/TWI828779B/zh active
- 2019-10-16 EA EA202191014A patent/EA202191014A1/ru unknown
- 2019-10-16 PE PE2021000513A patent/PE20211278A1/es unknown
- 2019-10-16 MA MA53898A patent/MA53898B1/fr unknown
- 2019-10-16 PT PT197863434T patent/PT3867244T/pt unknown
- 2019-10-16 SG SG11202103806VA patent/SG11202103806VA/en unknown
- 2019-10-16 RS RS20230140A patent/RS63988B1/sr unknown
- 2019-10-16 WO PCT/EP2019/078027 patent/WO2020079039A1/en active Application Filing
- 2019-10-16 US US16/654,030 patent/US11166958B2/en active Active
- 2019-10-16 IL IL282142A patent/IL282142B2/en unknown
- 2019-10-16 EP EP19786343.4A patent/EP3867244B1/en active Active
- 2019-10-16 BR BR112021004993-2A patent/BR112021004993A2/pt unknown
- 2019-10-16 PL PL19786343.4T patent/PL3867244T3/pl unknown
- 2019-10-16 FI FIEP19786343.4T patent/FI3867244T3/fi active
- 2019-10-16 JO JOP/2021/0075A patent/JOP20210075A1/ar unknown
- 2019-10-16 KR KR1020217014924A patent/KR20210079325A/ko unknown
- 2019-10-16 LT LTEPPCT/EP2019/078027T patent/LT3867244T/lt unknown
- 2019-10-16 AU AU2019362330A patent/AU2019362330B2/en active Active
- 2019-10-16 AR ARP190102937A patent/AR116711A1/es unknown
- 2019-10-16 ES ES19786343T patent/ES2940184T3/es active Active
- 2019-10-16 HR HRP20230249TT patent/HRP20230249T1/hr unknown
- 2019-10-16 MX MX2021004418A patent/MX2021004418A/es unknown
- 2019-10-16 SI SI201930465T patent/SI3867244T1/sl unknown
- 2019-10-16 HU HUE19786343A patent/HUE061891T2/hu unknown
- 2019-10-16 CA CA3113308A patent/CA3113308A1/en active Pending
- 2019-10-16 CN CN201980067936.7A patent/CN112888685B/zh active Active
- 2019-10-16 JP JP2021520981A patent/JP7093468B2/ja active Active
- 2019-10-16 DK DK19786343.4T patent/DK3867244T3/da active
- 2019-10-16 CR CR20210184A patent/CR20210184A/es unknown
-
2021
- 2021-04-07 CL CL2021000858A patent/CL2021000858A1/es unknown
- 2021-04-13 CO CONC2021/0004612A patent/CO2021004612A2/es unknown
- 2021-04-14 PH PH12021550834A patent/PH12021550834A1/en unknown
- 2021-04-14 SA SA521421756A patent/SA521421756B1/ar unknown
- 2021-04-16 DO DO2021000069A patent/DOP2021000069A/es unknown
- 2021-04-16 EC ECSENADI202127009A patent/ECSP21027009A/es unknown
- 2021-08-27 US US17/458,631 patent/US20210393644A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| Tafur et al. | Anestesia total intravenosa: de la farmacéutica a la farmacocinética | |
| HRP20211906T1 (hr) | Dalargin za upotrebu u liječenju akutne respiratorne virusne infekcije | |
| JP2018188483A5 (hr) | ||
| RS52256B (en) | THERAPEUTIC USES OF COMPOUNDS WITH COMBINED SERT, 5-HT3 AND 5-HT1A ACTIVITIES | |
| JP2016528301A5 (hr) | ||
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| HRP20202051T1 (hr) | Aril supstituirani pirimidini za uporabu kod infekcije virusom influence | |
| HRP20191869T1 (hr) | Fluoroindol derivati kao pozitivni alosterički modulatori muskarinskog m1 receptora | |
| HRP20240173T1 (hr) | Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije | |
| JP2019529541A5 (hr) | ||
| JP2017533972A5 (hr) | ||
| BRPI0411079A (pt) | composições farmacêuticas compreendendo atorvastatina, fabricadas sem granulação | |
| HRP20230249T1 (hr) | Derivati 4-pirazin-2-ilmetil-morfolina i njihova uporaba kao lijeka | |
| JP2021506971A5 (hr) | ||
| HRP20211726T1 (hr) | Derivati imidazopiridina i njihova uporaba kao lijeka | |
| US20160106774A1 (en) | Liquid pharmaceutical composition containing piroxicam and hyaluronic acid for the treatment of osteoarthritis | |
| RU2016105310A (ru) | Пиперазин-замещенные мостиковые производные спиро[2.4]гептана в качестве агонистов alx рецептора | |
| BR112019018185A2 (pt) | composição para tratar uma doença de articulação humana, e, kit. | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| BR112014004339A2 (pt) | suspensão oral | |
| EA201990419A1 (ru) | Слаборастворимый комплекс или его сольват, фармацевтическая композиция и их применение | |
| JP2019529569A5 (hr) | ||
| EA202192894A1 (ru) | Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний |